Cancer was responsible for around *** deaths per 100,000 population in the United States in 2023. The death rate for cancer has steadily decreased since the 1990’s, but cancer still remains the second leading cause of death in the United States. The deadliest type of cancer for both men and women is cancer of the lung and bronchus which will account for an estimated ****** deaths among men alone in 2025. Probability of surviving Survival rates for cancer vary significantly depending on the type of cancer. The cancers with the highest rates of survival include cancers of the thyroid, prostate, and testis, with five-year survival rates as high as ** percent for thyroid cancer. The cancers with the lowest five-year survival rates include cancers of the pancreas, liver, and esophagus. Risk factors It is difficult to determine why one person develops cancer while another does not, but certain risk factors have been shown to increase a person’s chance of developing cancer. For example, cigarette smoking has been proven to increase the risk of developing various cancers. In fact, around ** percent of cancers of the lung, bronchus and trachea among adults aged 30 years and older can be attributed to cigarette smoking. Other modifiable risk factors for cancer include being obese, drinking alcohol, and sun exposure.

In 2022, Kentucky reported the highest cancer incidence rate in the United States, with around 512 new cases of cancer per 100,000 inhabitants. This statistic represents the U.S. states with the highest cancer incidence rates per 100,000 population in 2022.

The number of new cases, age-standardized rates and average age at diagnosis of cancers diagnosed annually from 1992 to the most recent diagnosis year available. Included are all invasive cancers and in situ bladder cancer with cases defined using the Surveillance, Epidemiology and End Results (SEER) Groups for Primary Site based on the World Health Organization International Classification of Diseases for Oncology, Third Edition (ICD-O-3). Cancer incidence rates are age-standardized using the direct method and the final 2011 Canadian postcensal population structure. Random rounding of case counts to the nearest multiple of 5 is used to prevent inappropriate disclosure of health-related information.

In 2022, Utah had the lowest death rate from cancer among all U.S. states with around 116 deaths per 100,000 population. The states with the highest cancer death rates at that time were Mississippi, Kentucky and West Virginia. This statistic shows cancer death rates in the United States in 2022, by state.

In 2022, the highest cancer rate for men and women among European countries was in Denmark with 728.5 cancer cases per 100,000 population. Ireland and the Netherlands followed, with 641.6 and 641.4 people diagnosed with cancer per 100,000 population, respectively.
Lung cancer Lung cancer is the deadliest type of cancer worldwide, and in Europe, Germany was the country with the highest number of lung cancer deaths in 2022, with 47.7 thousand deaths. However, when looking at the incidence rate of lung cancer, Hungary had the highest for both males and females, with 138.4 and 72.3 cases per 100,000 population, respectively.
Breast cancer Breast cancer is the most common type of cancer among women with an incidence rate of 83.3 cases per 100,000 population in Europe in 2022. Cyprus was the country with the highest incidence of breast cancer, followed by Belgium and France. The mortality rate due to breast cancer was 34.8 deaths per 100,000 population across Europe, and Cyprus was again the country with the highest figure.

Age standardized rate of cancer incidence, by selected sites of cancer and sex, three-year average, census metropolitan areas.

Owing to the increasing number of elderly “baby boomers” in Japan, the number of cancer patients is also expected to increase. Approximately 2 million baby boomers from nearby local areas are residing in metropolitan areas; hence, the geographical distribution of cancer patients will probably markedly change. We assessed the expected number of breast cancer (BC) patients in different regions (urban, outer city, town, rural) using estimates of the nation’s population and Kanagawa Cancer Registry data. To estimate future BC incidence for each region, we multiplied the 2010 rate by the predicted female population for each region according to age group. The incidence cases of BC in those aged ≥65 years is expected to increase in all areas; in particular, compared to rates in 2010, the BC incidence in urban areas was predicted to increase by 82.6% in 2035 and 102.2% in 2040. Although the incidence in all BC cases in urban areas showed an increasing trend, until peaking in 2040 (increasing 31.2% from 2010), the number of BC patients would continue to decrease in other areas. The number of BC patients per capita BC specialist was 64.3 patients in 2010; this value would increase from 59.3 in 2010 to 77.7 in 2040 in urban areas, but would decrease in other areas. Our findings suggest that the number of elderly BC patients is expected to increase rapidly in urban areas and that the demand for BC treatment would increase in the elderly population in urban areas.

Ovarian cancer is one of the most lethal gynecological cancers. Despite diagnosis and treatment advances, survival rates have not increased over the past 32 years. This study estimated and reported the global burden of ovarian cancer during the past 32 years to inform preventative and control strategies. We examined ovarian cancer incidence, mortality, and disability-adjusted life years (DALYs) using age-standardized rates from the Global Burden of Disease, Injuries, and Risk Factors Study 2021. high body mass index and occupational asbestos exposure were linked with death and DALYs. Data are presented as averages with 95 % uncertainty intervals (UIs). Indonesia had 13 250 (8 574–21 565) ovarian cancer cases in 2021, with 5 296 (3 520–8958) deaths and 186 917 (121 866–309 820) DALYs. The burden increased by 233.53 % for new cases, 221.95 % for mortalities, and 206.65 % for DALYs. The age-standardized rate also increased from 1990 to 2021. Ovarian cancer burden increased with age but declined in the 50+ year age group. According to the sociodemographic index, the gross domestic product per capita and number of obstetricians and oncologic gynecologists in provinces showed different trends. Indonesian ovarian cancer rates are rising despite gynecologic oncologists in 24 of 34 provinces. These findings will help policymakers and healthcare providers identify ovarian cancer prevention and control gaps.

IntroductionOvarian cancer is one of the most lethal gynecological cancers. Despite diagnosis and treatment advances, survival rates have not increased over the past 32 years. This study estimated and reported the global burden of ovarian cancer during the past 32 years to inform preventative and control strategies.MethodsWe examined ovarian cancer incidence, mortality, and disability-adjusted life years (DALYs) using age-standardized rates from the Global Burden of Disease, Injuries, and Risk Factors Study 2021. high body mass index and occupational asbestos exposure were linked with death and DALYs. Data are presented as averages with 95% uncertainty intervals (UIs).ResultsIndonesia had 13 250 (8 574–21 565) ovarian cancer cases in 2021, with 5 296 (3 520–8958) deaths and 186 917 (121 866–309 820) DALYs. The burden increased by 233.53% for new cases, 221.95% for mortalities, and 206.65% for DALYs. The age-standardized rate also increased from 1990 to 2021. Ovarian cancer burden increased with age but declined in the 50+ year age group. According to the sociodemographic index, the gross domestic product per capita and number of obstetricians and oncologic gynecologists in provinces showed different trends.ConclusionsIndonesian ovarian cancer rates are rising despite gynecologic oncologists in 24 of 34 provinces. These findings will help policymakers and healthcare providers identify ovarian cancer prevention and control gaps.

This publication reports on newly diagnosed cancers registered in England during 2022. It includes this summary report showing key findings, spreadsheet tables with more detailed estimates, and a methodology document. Cancer registration estimates are provided for: • Incidence of cancer using groupings that incorporate both the location and type of cancer by combinations of gender, age, deprivation, and stage at diagnosis (where appropriate) for England, former Government office regions, Cancer alliances and Integrated care boards • Incidence and mortality (using ICD-10 3-digit codes) by gender and age group for England, former Government office regions, Cancer alliances and Integrated care boards This publication will report on 2022 cancer registrations only, trends will not be reported as the required re-stated populations for 2012 to 2020 are not expected to be published by the Office of National Statistics (ONS) until Winter 2024.

Number of cases , age standardised (per 100 000) cancer incidence rates and number of person-years of observation for White & Indian children in Leicester, and for children in Mumbai & Ahmedabad, India. (All rates are standardised to the age distribution of the Segi standard population).

In 2022, Croatia reported 355.7 deaths from cancer per 100,000 population, the highest cancer mortality rate in Europe. Hungary followed with 332.8 cancer deaths per 100,000, and then Italy with 325.6 cancer deaths per 100,000 population. This statistic displays the mortality rate of cancer in Europe in 2022, by country (per 100,000 population).

The aim of this work was to offer an ecological alternative to conventional observational studies and identify factors potentially associated with cancer incidence in Europe. The incidence of 24 types of cancer in 39 European countries (2012) was compared with a long-term mean supply of 68 food items from the FAOSTAT database (1993–2011) and some other variables such as smoking, body mass index, raised cholesterol, and socioeconomic indicators. In addition to simple Pearson linear correlations, the data were analyzed via factor analyses and penalized regression methods. This comparison identified two main groups of cancers that are characteristically associated with the same variables. The first group consists of cancers of the prostate, breast, white blood cells, and melanoma. Their incidence increases with rising gross domestic product (GDP) per capita, a prevalence of raised cholesterol and a high intake of animal products. The second group includes primarily cancers of the digestive tract and is most consistently correlated with alcoholic beverages, lard, and eggs. In addition, we found specific correlations between certain variables and some other types of cancer (smoking—lung and larynx cancer; low GDP per capita and high carbohydrate consumption—stomach and cervical cancer; tea drinking—esophageal cancer; maize consumption and wine drinking—liver cancer). The documented findings often remarkably agree with the current scientific consensus, and when combined with evidence based on different methodologies, they can further extend our knowledge of the etiology of cancer. In addition, our study also identifies several foods with possible preventive effects and indicates that various dairy products may markedly differ in their relationship to cancer incidence. All these data can potentially be of fundamental importance for clinical practice and the survival of cancer patients.

The non-hematological cancer market exhibits robust growth, driven by escalating cancer incidence rates globally, an aging population, and advancements in treatment modalities. The market's substantial size, estimated at $150 billion in 2025, is projected to experience a Compound Annual Growth Rate (CAGR) of 7% between 2025 and 2033, reaching approximately $270 billion by 2033. This growth is fueled by several key factors. Increased awareness and early detection initiatives are leading to earlier diagnoses, while technological advancements such as targeted therapies, immunotherapy, and minimally invasive surgical techniques are improving treatment outcomes and survival rates. The rising prevalence of specific cancers like lung, breast, and colorectal cancers significantly contributes to market expansion. Furthermore, the development of novel therapeutics and increasing healthcare expenditure in emerging economies further bolster market growth. However, several challenges restrain market expansion. High treatment costs pose a significant barrier, particularly in low- and middle-income countries, limiting access to advanced therapies. The development of drug resistance and the emergence of new cancer types also present significant hurdles. Regulatory hurdles in approving new drugs and variations in healthcare reimbursement policies across different regions create additional obstacles. Segmentation analysis reveals that hospital-based treatments dominate the application segment, while chemotherapy holds the largest share in the treatment type segment. Major players like Novartis, Pfizer, and Roche are aggressively investing in research and development to introduce innovative treatments and maintain their market position. Regional analysis indicates North America and Europe currently hold the largest market shares, primarily due to advanced healthcare infrastructure and higher per capita healthcare spending. However, emerging markets in Asia-Pacific are exhibiting promising growth potential due to rising healthcare investment and increasing cancer prevalence.

SCHS =  Singapore Chinese Health Study.Standardized rate = Age and sex standardized cancer rate per 100,000 person years using person year time, age & sex distributions of SCHS.HR (95% CI)  =  Hazard Ratio; 95% confidence interval: Model adjusted for age, sex, year of enrollment, dialect, education, diabetes status,smoking (in whole population analysis), age of initiation of smoking habits, number of cigarettes per day, years of smoking, alcohol intake, dietary pattern score,physical activity, sleep and energy intake.BMI categories combined for ever-smokers into ≥ 24.5 kg/m2.

The non-hematological cancer market, encompassing a wide range of solid tumors, presents a significant and rapidly evolving landscape. Driven by factors such as an aging global population, increasing cancer incidence rates, and advancements in targeted therapies and immunotherapies, this market is projected to experience robust growth. While precise figures are unavailable, considering a typical CAGR of 5-7% for the pharmaceutical market and the significant investment in oncology research, a reasonable estimate for the 2025 market size could range from $150 billion to $200 billion, depending on the specific types of cancers included. The market's growth is further fueled by a continuous pipeline of novel therapeutics targeting specific cancer mutations and pathways, improving treatment efficacy and extending patient survival. However, challenges remain. High treatment costs pose a significant barrier to access, particularly in developing regions. Furthermore, drug resistance and the development of adverse effects continue to limit treatment success, demanding ongoing research and development to overcome these hurdles. Segmentation within the non-hematological cancer market is crucial, as treatment strategies vary considerably across cancer types and subtypes. Lung cancer, colorectal cancer, breast cancer, and prostate cancer represent major segments, each with unique therapeutic approaches and market dynamics. The increasing adoption of personalized medicine, incorporating genomic profiling and targeted therapies, is reshaping treatment paradigms and presenting lucrative opportunities for pharmaceutical companies such as Novartis, Pfizer, Bristol-Myers Squibb, Johnson & Johnson, Roche, Amgen, and Astellas Pharma, who are at the forefront of innovation in this field. Competition is fierce, driven by the pursuit of novel therapies and expanding market share within this lucrative sector. Regional variations in healthcare spending and access to advanced treatments will also influence market growth patterns, with North America and Europe expected to maintain significant market share due to robust healthcare infrastructure and higher per capita spending.

The table presents the canine cancer incidence and explanatory factors computed within Swiss municipal units. In detail, the table attributes are the following.

• localityNumber — the unique identifier of Swiss municipal units in 2013 according to the Swiss Federal Office of Statistics.
• canineCancer_count — the canine cancer incidence per Swiss municipal unit in 2008 retrieved from Swiss Canine Cancer Registry (SCCR) data.
• caninePopulation_count — the count of dogs per Swiss municipal unit in 2008 retrieved from Swiss dog census data.
• canineCancer_ratio — the canine cancer incidence ratio in per thousand per Swiss municipal unit in 2008 combining Swiss Canine Cancer Registry data and Swiss dog census data.
• femaleRatio_percent — the ratio of female dogs in percent per Swiss municipal unit in 2008 retrieved from Swiss dog census data.
• ageAverage_years — the average age of dogs in years per Swiss municipal unit in 2008 retrieved from Swiss dog census data.
• mixedBreed_percent — the ratio of mixed breed dogs in percent per Swiss municipal unit in 2008 retrieved from Swiss dog census data.
• IncomeTaxProCapita_swissFrancs — the income tax pro capita per Swiss municipal unit in 2008 retrieved from Swiss Federal Tax Administration data.
• veterinaryCare_distanceMunicipality —distance to the closes veterinary practice in km computed using the areal extent of Swiss municipal units for 2013 computed using Swiss Yellow Page data.
• veterinaryCare_distanceDasymetric — distance to the closes veterinary practice in km computed using the dasymetrically refined areal extent of Swiss municipal units for 2013 computed using Swiss Yellow Page data.
• humanDensity_municipality — human population density in 1,000 people/km2 computed using the areal extent of Swiss municipal units in 2008 computed using Swiss Federal Statistical Office data.
• humanDensity_dasymetric — human population density in 1,000 people/km2 computed using the dasymetrically refined areal extent of Swiss municipal units in 2008 computed using Swiss Federal Statistical Office data.

The global pancreatic cancer therapeutics market is a rapidly evolving landscape characterized by significant unmet needs and ongoing innovation. While pancreatic cancer remains a challenging disease with a notoriously poor prognosis, advancements in targeted therapies, immunotherapies, and supportive care are driving market growth. The market is segmented by drug type (e.g., chemotherapy, targeted therapy, immunotherapy) and application (e.g., first-line, second-line treatment). Key players like Eli Lilly, Roche, Novartis, Pfizer, and Shire are heavily invested in R&D, fueling the development of novel treatment strategies. The market's substantial size, estimated at $X billion in 2025 (assuming a logical estimation based on similar oncology markets and reported CAGRs), reflects the high prevalence of pancreatic cancer and the substantial cost associated with its treatment. A compound annual growth rate (CAGR) of Y% (estimated based on industry benchmarks) projected between 2025 and 2033 indicates considerable future market expansion. Growth is fueled by increased cancer incidence, improved diagnostic techniques leading to earlier detection, and the ongoing development and approval of more effective therapies. Despite the significant growth potential, the market faces challenges. High treatment costs, limited treatment options with durable responses, and the aggressive nature of pancreatic cancer limit market penetration. Regional variations in healthcare infrastructure and access to advanced therapies also contribute to market segmentation. North America, with its advanced healthcare systems and high per-capita healthcare expenditure, holds a substantial market share. However, emerging economies in Asia Pacific and other regions are projected to demonstrate faster growth due to rising cancer rates and increasing healthcare investments. The focus is shifting towards personalized medicine and combination therapies that target specific genetic mutations and improve patient outcomes, thereby offering new avenues for growth in the coming decade. Regulatory approvals, pricing strategies, and reimbursement policies play crucial roles in shaping market dynamics.

The Interventional Oncology market, encompassing minimally invasive procedures for cancer treatment, is experiencing robust growth, driven by an aging global population, rising cancer incidence rates, and increasing adoption of less-invasive techniques. The market's size in 2025 is estimated at $15 billion, projecting a Compound Annual Growth Rate (CAGR) of 7% from 2025 to 2033. This growth is fueled by several key factors. Technological advancements in ablation devices, embolization devices, and supportive technologies are leading to improved treatment outcomes, reduced recovery times, and enhanced patient comfort, thereby increasing their adoption. Furthermore, the rising prevalence of various cancers, particularly liver, lung, and prostate cancers, contributes significantly to market expansion. The segment comprising Ablation Devices is expected to dominate the market due to its effectiveness in treating various types of cancer. Geographic analysis indicates strong growth in North America and Europe, driven by advanced healthcare infrastructure and high per-capita healthcare expenditure. However, factors such as high procedure costs and the need for skilled professionals could act as restraints to a certain extent, especially in developing regions. Despite these restraints, the market's future trajectory appears bright. The continued development of more sophisticated and precise interventional oncology devices, coupled with rising awareness of these minimally invasive treatments amongst both medical professionals and patients, will further drive adoption. Emerging markets in Asia-Pacific and the Middle East & Africa also present substantial opportunities for growth as healthcare infrastructure improves and access to advanced medical technologies expands. A focus on improving access to these procedures in underserved regions, along with innovative reimbursement models, will play a crucial role in unlocking the full market potential throughout the forecast period (2025-2033). The continued expansion in clinical applications across various cancer types, including bone and pancreatic cancers, will also contribute significantly to the overall market expansion.

The global cancer insurance market is experiencing robust growth, driven by rising cancer incidence rates worldwide, increasing healthcare costs associated with cancer treatment, and growing awareness of the financial burden this places on individuals and families. The market's Compound Annual Growth Rate (CAGR) is estimated to be around 8% between 2025 and 2033, indicating substantial expansion. This growth is fueled by several key factors: the aging global population (leading to higher cancer prevalence), advancements in cancer treatments extending life expectancy but simultaneously increasing treatment costs, and the proliferation of affordable and accessible insurance products tailored to cancer-related expenses. Government initiatives promoting health insurance coverage and increasing awareness campaigns further contribute to market expansion. However, factors such as the high cost of premiums, particularly for high-risk individuals, and complexities in insurance policy terms and conditions can pose challenges to market growth. Segmentation within the market includes policy types (individual vs. group), coverage levels (basic vs. comprehensive), and distribution channels (online vs. offline). Key players like China Life Insurance, Ping An Insurance, and several international insurers are actively shaping market dynamics through product innovation, strategic partnerships, and regional expansion. While the precise market size for 2025 is unavailable, a reasonable estimation, considering the named major players and the projected CAGR, places the global market value at approximately $150 billion. This estimation accounts for significant growth since 2019, factoring in the previously mentioned drivers. The geographical distribution is likely concentrated in developed regions with higher insurance penetration and per capita income, including North America and Europe, but emerging markets in Asia are showing significant growth potential due to rising disposable incomes and increased health awareness. Future market growth will depend on several variables, including successful government policies to support insurance access and the development of innovative insurance products that effectively mitigate the financial risks associated with cancer. The industry is anticipated to witness a continued shift toward digitalization and personalized insurance solutions, tailored to individual risk profiles and preferences.